Neurogene (NGNE) Long-Term Debt Issuances (2014)

Neurogene's (NGNE) quarterly Long-Term Debt Issuances came in at -$5.2 million in Q4 2014, down 300.0% on a QoQ basis from $2.6 million in Q1 2014.

Neurogene (NGNE) Long-Term Debt Issuances (2014) Analysis & Trends

Neurogene (NGNE) has 1 years of Long-Term Debt Issuances data on file, last reported at -$5.2 million in Q4 2014.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$5.2 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was -$2.6 million (changed N/A YoY) and the FY2014 annual result came in at -$2.6 million, down 208.7% from the prior year.
Long-Term Debt Issuances declined to -$5.2 million in Q4 2014, from $2.6 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $2.6 million in Q1 2014 to a low of -$5.2 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Neurogene	815.03 Mn	815.03 Mn	-	-

Download Data